Glucuronides in anti-cancer therapy.

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Glucuronide prodrugs demonstrate potential in cancer treatment by enhancing specificity and minimizing systemic toxicity.
• Prodrug monotherapy (PMT) relies on increased beta-glucuronidase activity within tumors to activate prodrugs into cytotoxic agents.
• This targeted activation ensures that highly toxic compounds are released specifically at the tumor site.

Purpose of the Study:

• To explore the multifaceted applications of glucuronide prodrugs in anti-cancer strategies.
• To highlight methods for improving prodrug specificity and potency in cancer therapy.
• To discuss the integration of prodrugs into advanced therapeutic approaches.

Main Methods:

• Investigating prodrug monotherapy (PMT) utilizing tumor-specific beta-glucuronidase activity.
• Examining antibody-directed enzyme prodrug therapy (ADEPT) by combining prodrugs with monoclonal antibodies targeting tumor antigens.
• Evaluating combined chemo- and radio-therapy of cancer (CCRT) strategies incorporating radionuclides into prodrugs.
• Assessing the use of prodrugs in liposome-mediated drug delivery systems.

Main Results:

• Glucuronide prodrugs show promise for targeted cancer therapy, reducing systemic side effects.
• PMT effectively utilizes elevated tumor beta-glucuronidase for localized prodrug activation.
• ADEPT enhances specificity through antibody targeting of tumor antigens.
• Incorporation of radionuclides in CCRTC strategies significantly boosts prodrug potency.
• Liposome modification with prodrugs facilitates efficient anti-cancer drug delivery.

Conclusions:

• Glucuronide prodrugs represent a versatile platform for advanced cancer treatment modalities.
• Strategies like PMT, ADEPT, and CCRTC offer improved specificity and efficacy.
• Further development of prodrug-based therapies holds significant potential for improving patient outcomes in oncology.